Asian Indian Prediabetes Study

Pre Diabetes Clinical Trial

— AIPS  

Official title:

Diet and Lifestyle Intervention Strategies to Treat β-cell Dysfunction and Insulin Resistance in Asian Indians

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04507685
• Other study ID #: 2019-078
• Status: Completed
• Phase: N/A
• Start date: October 19, 2020
• Est. completion date: February 1, 2023

Study information

• Verified date: November 2023
• Source: Singapore Institute for Clinical Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Compared to other races, Indians have higher insulin resistance, poorer pancreatic function and a greater risk of developing diabetes, highlighting the importance of early strategies for improving insulin sensitivity and improving pancreatic function in Indians to prevent diabetes and lower the risk of heart disease. A low carbohydrate diet can deplete fat from undesirable places, such as fat around organs in the abdominal cavity. In this study, we will determine if restriction of dietary carbohydrates will deplete fat in the pancreas and liver, and improve insulin sensitivity and early insulin secretion in Indians. These changes may prevent diabetes from developing. Hepatic and pancreatic fat will be measured using magnetic resonance imaging. Insulin sensitivity and secretion will be measured during an oral glucose tolerance test. In addition, this study will investigate if the higher insulin resistance in Indians is due to genes that cause the inability to store fat in the legs. The results on the type of diet that is more effective for reducing pancreatic and hepatic fat is important for informing dietary guidelines on the use of low carbohydrate diets for diabetes prevention, particularly in Indians who have a higher risk of developing diabetes.

Description:

Compared to other races, Indians have a greater risk of developing type 2 diabetes (T2D), increased insulin resistance (IR) and more rapid decline in β-cell function, highlighting the urgency and importance of early intervention strategies for improving insulin sensitivity and preserving/improving β-cell function to prevent T2D and mitigate against the increased vascular disease risk. Preliminary findings show a reduction in glycemic load selectively depletes visceral and ectopic lipid and improves insulin sensitivity and β-cell function in non-diabetic adults. The proposed research will investigate if the phenotypic features increasing T2D risk in individuals of Indian ancestry (IR and impaired β-cell function) can be favorably modified by a low glycemic (LG) intervention, and if the increased IR is attributable to genetic factors regulating adipocyte differentiation and function. These research objectives will be achieved through a 24-week randomized controlled trial (RCT) comparing isocaloric LG versus control diets in Indians with prediabetes. Compared to individuals in the control group, those on the LG diet are expected to have greater ectopic (pancreas, liver, visceral and intramyocellular) fat depletion assessed with MRI/MRS, and improvements in first phase insulin secretion and insulin sensitivity assessed with the C-peptide model and oral minimal model, respectively during an OGTT. Reductions in hepatic and pancreatic lipids will be associated with improvements in first-phase β-cell response. Individuals with a greater number of risk alleles from a 53-SNP IR genetic risk score will have lower insulin sensitivity and leg fat, supporting the notion that impaired adipocyte differentiation leading to limited peripheral adipose expansion capacity is an important etiological factor underpinning IR cardiometabolic disease in Indians. The results will broaden the evidence base for effective prevention strategies in this high risk population by investigating the effect of the proposed diet intervention on underlying physiological and molecular mechanisms implicated in the pathophysiology of T2D in Indians.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 53
• Est. completion date: February 1, 2023
• Est. primary completion date: January 27, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years to 50 Years

Eligibility

Inclusion Criteria:

• Male or female
• Asian Indian ethnicity
• Age between 21-50 years
• BMI not greater than 35 or less than 25
• Prediabetes (based on results from an OGTT conducted in the last 3 months):
• Impaired Fasting Glucose (IFG) which is a fasting blood glucose level of between 5.6 to 6.9 mmol/l and/or
• Impaired Glucose Tolerance (IGT) which is a blood glucose level of 7.8 to 11.0 mmol/l, 2 hours after the OGTT but below 7.0 mmol/l in the fasting state.
• Not have type 1 or type 2 diabetes
• Not on any diabetes medications that affect insulin sensitivity e.g. metformin, glitazones
• No abnormality of clinical significance on medical history
• If female, not pregnant or breast feeding
• No history of coronary artery disease or cardiac (heart) abnormalities
• Participants must understand the procedures involved and agree to participate in the study by giving full informed, written consent

Exclusion Criteria:

• BMI greater than 35 or less than 25
• Weight gain or loss of more than 5% over the past 3 months
• Have anaemia (low haemoglobin/ red blood cell levels), a malignancy (cancer), abnormal liver function, any significant endocrinopathy (e.g. thyroid problems), or a history of metabolic disease such as liver, kidney, cardiovascular, respiratory or gastrointestinal disease.
• Have high uncontrolled hypertension (resting seated blood pressure >160/100 mmHg)
• Taking medications that may affect glucose metabolism e.g. steroids, thiazide diuretics at doses>25mg/day.
• History of smoking or using nicotine products during the 6 months prior to study
• History of heavy alcohol consumption (> 5 standard drinks/day)
• Inability to limit alcohol consumption for study duration
• Lactose Intolerant or have a nut allergy
• Have depression
• Have a musculoskeletal injury, joint or peripheral vascular disease sufficient to impede exercise (such as hip arthritis, foot, ankle problems or pain)
• Have severe exercise-induced asthma
• Participating in a regular aerobic or resistance exercise program
• Currently on a weight reducing diet or have an eating disorder
• Contraindications for MRI e.g. if you have certain metallic implants/devices such as heart valves of a cardiac pacemaker which may be affected by the magnetic field
• Unwilling to be randomized to either diet group
• Extended absences due to travel or other commitments
• Unable to comprehend or cope with study requirements

Related Conditions & MeSH terms

• Pre Diabetes
• Prediabetic State

Intervention

Other:
• Lifestyle (Diet and Exercise)
The LG diet will comprise 20% carbohydrate, 30% protein, and 50% fat (<10% saturated fat). It will have a low glycaemic load; include plant and animal protein; non-starchy vegetables and salad greens; and some low-sugar fruit. Participants will be encouraged to incorporate a variety of foods rich in monounsaturated and polyunsaturated fats in their diet. The control diet will comprise 50% carbohydrate, 20% protein and 30% total fat (<10% saturated fat). It will reflect the Health Promotion Board's (HPB) recommendations to reduce dietary fat, emphasize wholegrains and include a variety of fruits and vegetables. In contrast to the LG diet, the control diet will have a higher glycaemic load with a greater proportion of energy derived from unrefined carbohydrate foods. Concurrent to the dietary intervention and consistent with physical activity guidelines, all participants will undertake a 60-min structured exercise program incorporating aerobic/ resistance exercises 3-4 days/week.

Locations

Country	Name	City	State
Singapore	Singapore Institute for Clinical Sciences (SICS)	Singapore

Sponsors (3)

Lead Sponsor	Collaborator
Singapore Institute for Clinical Sciences	Almond Board of California, National Medical Research Foundation (NMRC) Singapore

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in respiratory quotient (RQ)	Respiratory quotient (RQ) to assess substrate utilization by indirect calorimetry.	Week 0, 8 and 24
Other	Change in blood ketone (ß-hydroxybutyrate, ßHB) concentrations	A marker of carbohydrate intake	Week 0, 8 and 24
Other	Change in 24-h urinary urea to creatinine ratio	A marker of protein intake	Week 0, 8 and 24
Other	Change in Physical activity levels	Assessed with 7 consecutive days of triaxial accelerometry	Week 0, 8 and 24
Other	Change in Exercise Classes attendance		24 weeks
Other	Change in dietary intake (diet checklists)		24 weeks
Primary	Change in ß-cell Function [First-phase ß-cell response (PhiD)]	First-phase ß-cell response (PhiD) will be calculated from blood glucose and C-peptide data during a 3h 75g oral glucose tolerance test (OGTT) using the C-peptide minimal model.	Week 0, 8 and 24
Primary	Change in Insulinogenic index (?C-peptide/?glucose during the first 30 minutes of the OGTT)	?C-peptide/?glucose during the first 30 minutes of the OGTT will be calculated as an index of early insulin secretion (Insulinogenic index).	Week 0, 8 and 24
Primary	Change in Incremental AUC	Incremental AUC over 180 minutes of the OGTT will be calculated for glucose, insulin, and C-peptide.	Week 0, 8 and 24
Primary	Change in Insulin sensitivity (Oral Minimal model)	Insulin sensitivity will be calculated from blood glucose, insulin and C-peptide during a 3h 75g oral glucose tolerance test (OGTT) using both the oral minimal model	Week 0, 8 and 24
Primary	Change in Matsuda index for whole body insulin sensitivity		Week 0, 8 and 24
Secondary	Change in Body fat distribution	Body fat distribution will be imaged and quantified using MRI and MRS. Abdominal fat will be segmented to identify and quantify subcutaneous (deep and superficial) and visceral fat compartments. Lower body gluteal fat compartment will also be imaged and quantified. Fat within liver, pancreas and skeletal muscle fibers will be determined by MRI / MRS.	Week 0, 8 and 24
Secondary	Change in Weight (kg)		Week 0, 8 and 24
Secondary	Change in Blood Pressure		Week 0, 8 and 24
Secondary	Change in Body Composition- Total body fat	Total body fat (kg) will be assessed using DXA	Week 0, 8 and 24
Secondary	Change in Body Composition- Total lean mass	Total lean mass (kg) will be assessed using DXA	Week 0, 8 and 24
Secondary	Genotyping analyses	Genomic DNA isolated from blood samples will be analysed	Week 0
Secondary	Change in Blood Lipids (total cholesterol, HDL-C, TAG, lipoprotein subfractions)		Week 0, 8 and 24
Secondary	Change in liver enzymes		Week 0, 8 and 24
Secondary	Change in inflammatory markers (e.g. IL-6, TNFa and CRP)		Week 0, 8 and 24
Secondary	Change in satiety hormones (e.g. leptin, ghrelin, GIP and GLP-1).		Week 0, 8 and 24
Secondary	Lipidomics	Lipidomics evaluation of several lipid classes including sphingolipids (sphingomyelins, ceramides and glycosphingolipids) in plasma	Week 0, 8 and 24
Secondary	Change in Plasma phospholipid fatty acid (FA) profile		Week 0, 8 and 24
Secondary	Change in Gut microbiota composition	Gut microbiota composition will be assessed by 16S or shotgun metagenomic sequencing	Week 0, 8 and 24
Secondary	Change in Faecal characteristics- including short chain fatty acids (SCFAs).		Week 0, 8 and 24